Cargando…

Inhibition of cyclin dependent kinase 9 by dinaciclib suppresses cyclin B1 expression and tumor growth in triple negative breast cancer

Cyclin-dependent kinases (CDKs) are potential cancer therapeutic targets because of their critical role in promoting cell growth. Dinaciclib is a novel CDK inhibitor currently under clinical evaluation for the treatment of advanced malignancies. In this study, we demonstrated the anti-tumor activity...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rajput, Sandeep, Khera, Nimmish, Guo, Zhanfang, Hoog, Jeremy, Li, Shunqiang, Ma, Cynthia X.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5302958/ https://www.ncbi.nlm.nih.gov/pubmed/27486754 http://dx.doi.org/10.18632/oncotarget.10870

Ejemplares similares

Dinaciclib, a cyclin-dependent kinase inhibitor, suppresses cholangiocarcinoma growth by targeting CDK2/5/9
por: Saqub, Hera, et al.
Publicado: (2020)

Activation of the Kynurenine Pathway in Human Malignancies Can Be Suppressed by the Cyclin-Dependent Kinase Inhibitor Dinaciclib
por: Riess, Christin, et al.
Publicado: (2020)

A cyclin-dependent kinase inhibitor, dinaciclib in preclinical treatment models of thyroid cancer
por: Lin, Shu-Fu, et al.
Publicado: (2017)

Dinaciclib as an effective pan-cyclin dependent kinase inhibitor in platinum resistant ovarian cancer
por: Howard, David, et al.
Publicado: (2022)

PI3K inhibition enhances the anti-tumor effect of eribulin in triple negative breast cancer
por: Rajput, Sandeep, et al.
Publicado: (2019)

Cyclin-dependent kinase inhibitor dinaciclib potently synergizes with cisplatin in preclinical models of ovarian cancer
por: Chen, Xiu-Xiu, et al.
Publicado: (2015)

The Anti-Melanoma Activity of Dinaciclib, a Cyclin-Dependent Kinase Inhibitor, Is Dependent on p53 Signaling
por: Desai, Brijal M., et al.
Publicado: (2013)

Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias
por: Gojo, Ivana, et al.
Publicado: (2013)

Dinaciclib is a Novel Cyclin Dependent Kinase Inhibitor with Significant Clinical Activity in Relapsed and Refractory Chronic Lymphocytic Leukemia
por: Flynn, Joseph, et al.
Publicado: (2015)

Synthetic lethality of cyclin-dependent kinase inhibitor Dinaciclib with VHL-deficiency allows for selective targeting of clear cell renal cell carcinoma
por: Nelson, Luke J, et al.
Publicado: (2022)

Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies
por: Mita, Monica M, et al.
Publicado: (2017)

Protein Phosphatase 1H, Cyclin-Dependent Kinase Inhibitor p27, and Cyclin-Dependent Kinase 2 in Paclitaxel Resistance for Triple Negative Breast Cancers
por: Hur, Saem, et al.
Publicado: (2020)

Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy: Miniperspective
por: Sonawane, Yogesh A., et al.
Publicado: (2016)

Cyclin-dependent kinases
por: Malumbres, Marcos
Publicado: (2014)

A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies
por: Nemunaitis, John J, et al.
Publicado: (2013)

ERβ inhibits cyclin dependent kinases 1 and 7 in triple negative breast cancer
por: Reese, Jordan M., et al.
Publicado: (2017)

The Regulation of Cyclins and Cyclin-Dependent Kinases in the Development of Gastric Cancer
por: Javed, Aadil, et al.
Publicado: (2023)

Functional Differentiation of Cyclins and Cyclin-Dependent Kinases in Giardia lamblia
por: Kim, Juri, et al.
Publicado: (2023)

Identification of novel inhibitors against Cyclin Dependent Kinase 9/Cyclin T1 complex as: Anti cancer agent
por: Hussain, Afzal, et al.
Publicado: (2017)

Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib
por: Bagegni, Nusayba, et al.
Publicado: (2017)

Effects of Cyclin Dependent Kinase 9 inhibition on zebrafish larvae
por: Matrone, Gianfranco, et al.
Publicado: (2016)

Identification and Functional Characterisation of CRK12:CYC9, a Novel Cyclin-Dependent Kinase (CDK)-Cyclin Complex in Trypanosoma brucei
por: Monnerat, Séverine, et al.
Publicado: (2013)

Phosphorylation of cyclin O, a novel cyclin family protein containing a cyclin-like domain, is involved in the activation of cyclin-dependent kinase 2
por: KIM, DO HYUNG, et al.
Publicado: (2014)

Perspective of Cyclin-dependent kinase 9 (CDK9) as a Drug Target
por: Kryštof, Vladimír, et al.
Publicado: (2012)

Cyclin-dependent kinases in C. elegans
por: Boxem, Mike
Publicado: (2006)

The Renaissance of Cyclin Dependent Kinase Inhibitors
por: Ettl, Tobias, et al.
Publicado: (2022)

The Cyclin-Dependent Kinase Ortholog pUL97 of Human Cytomegalovirus Interacts with Cyclins
por: Graf, Laura, et al.
Publicado: (2013)

Deciphering the binding behavior of flavonoids to the cyclin dependent kinase 6/cyclin D complex
por: Zhang, Jingxiao, et al.
Publicado: (2018)

Cyclin-Dependent Kinase 9 Activity Regulates Neutrophil Spontaneous Apoptosis
por: Wang, Keqing, et al.
Publicado: (2012)

Antitumor effects of cyclin dependent kinase 9 inhibition in esophageal adenocarcinoma
por: Tong, Zhimin, et al.
Publicado: (2017)

Small molecule inhibitors of cyclin-dependent kinase 9 for cancer therapy
por: Alsfouk, Aisha
Publicado: (2021)

Cyclin-dependent kinase 9 (CDK9) predicts recurrence in Middle Eastern epithelial ovarian cancer
por: Parvathareddy, Sandeep Kumar, et al.
Publicado: (2021)

Cyclin-Dependent Kinase Inhibitors Function as Potential Immune Regulators via Inducing Pyroptosis in Triple Negative Breast Cancer
por: Xu, Tao, et al.
Publicado: (2022)

Concomitant Presence of p16/Cyclin‐dependent Kinase 4 and Cyclin D/Cyclin‐dependent Kinase 4 omplexes in LNCaP Prostatic Cancer Cell Line
por: Itoh, Noriyuki, et al.
Publicado: (1997)

Proteomic Resistance Biomarkers for PI3K Inhibitor in Triple Negative Breast Cancer Patient-Derived Xenograft Models
por: Guo, Zhanfang, et al.
Publicado: (2020)

Requirement for A-type cyclin-dependent kinase and cyclins for the terminal division in the stomatal lineage of Arabidopsis
por: Yang, Kezhen, et al.
Publicado: (2014)

Prediction of Cyclin-Dependent Kinase Phosphorylation Substrates
por: Chang, Emmanuel J., et al.
Publicado: (2007)

Cyclin-dependent kinase control of motile ciliogenesis
por: Vladar, Eszter K, et al.
Publicado: (2018)

Cyclin-dependent kinases and rare developmental disorders
por: Colas, Pierre
Publicado: (2020)

Therapeutic targeting of transcriptional cyclin-dependent kinases
por: Galbraith, Matthew D., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_m3bdlm0mdi16udcsrbsg70t955